Elsevier

Journal of Thoracic Oncology

Volume 10, Issue 9, September 2015, Pages 1370-1374
Journal of Thoracic Oncology

Brief Report
Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study

https://doi.org/10.1097/JTO.0000000000000621Get rights and content
Under an Elsevier user license
open archive

Abstract

The Implementation of per Sonalized medicine in NSCLC in Central Europe: EGFR testing, Histopathology, and clinical feaTures (INSIGHT) observational study assessed both implementation of epidermal growth factor receptor (EGFR) mutation testing and treatment of patients with advanced EGFR mutation-positive non–small-cell lung cancer (NSCLC) in a real-world setting in Central Europe. A total of 1785 patients from 14 cancer centers of six Central European countries were enrolled. EGFR mutations were detected in tumors of 13.8% of the patients. More than 70% of patients with advanced EGFR mutation-positive NSCLC received EGFR tyrosine kinase inhibitors as first-line therapy. The INSIGHT study demonstrated the establishment of EGFR mutation testing, a mutation rate consistent with other Caucasian patients populations, and adherence to current guidelines regarding treatment of patients with EGFR mutation-positive tumors in Central Europe.

Key Words

Targeted therapy
INSIGHT
EGFR mutations
Molecular analysis

Cited by (0)

The study was designed by the members of the Steering committee: TC, PB, RD, WO, HP, PB, LD, ZZ and RP All authors contributed to the acquisition and interpretation of data. The manuscript was prepared by PB, ZZ and RP, and its final version was approved by all authors.

Disclosure: Dr. Robert Pirker received speaker's fee and honoraria for advisory boards from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Serono, Pfizer, Roche, and Synta. Dr. Tanja Cufer received honoraria for advisory boards from Boehringer Ingelheim and Pfizer. Dr. Rodryg Ramlau has received honoraria for advisory boards from Boehringer Ingelheim, Eli Lilly, and MSD. All other authors declare no conflict of interest.

This study was supported by an unrestricted grant from Boehringer Ingelheim RCV, Vienna, Austria.